These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Editorial: Thalassemia major: a problem of iron overload. Stockman JA; Oski FA Ann Intern Med; 1974 Aug; 81(2):262-3. PubMed ID: 4846109 [No Abstract] [Full Text] [Related]
23. Glucose tolerance and chelation therapy in patients with thalassaemia major. Capra L; Atti G; De Sanctis V; Candini G Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709 [No Abstract] [Full Text] [Related]
24. Therapeutic application of iron chelators--present state and research trends. Peter HH J Pharmacol; 1985; 16(4):365-71. PubMed ID: 4094434 [No Abstract] [Full Text] [Related]
25. [The value of nuclear magnetic resonance in the study of iron overload in thalassemia patients]. Perrimond H; Chagnon C; Moulanier I; Michel G; Guidicelli H; Bernard PJ Ann Pediatr (Paris); 1991 Mar; 38(3):175-84. PubMed ID: 2039185 [TBL] [Abstract][Full Text] [Related]
27. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives. Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996 [No Abstract] [Full Text] [Related]
28. Pathogenesis and management of iron overload in thalassemia. Hershko C Haematologica; 1975 Jun; 60(2):241-8. PubMed ID: 808456 [No Abstract] [Full Text] [Related]
29. Iron excretion in thalassemia after the administration of chelating agents. Markum AH; Iskandar W; Keng KL; Odang O Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722 [No Abstract] [Full Text] [Related]
30. Clinical removal of iron. Propper R; Nathan D Annu Rev Med; 1982; 33():509-19. PubMed ID: 6282184 [No Abstract] [Full Text] [Related]
31. [Secondary iron overload]. Galacteros F Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():44-8. PubMed ID: 9827215 [No Abstract] [Full Text] [Related]
33. [Recommendations for therapy of juvenile thalassemia major]. Siller V; Frank M Fortschr Med; 1980 Nov; 98(44):1720-9. PubMed ID: 7007189 [TBL] [Abstract][Full Text] [Related]
34. [Effects of ascorbic acid on desferrioxamine-induced siderinuria]. Bosello O; Mengoli C; Rossi G Fracastoro; 1971; 64(5):310-9. PubMed ID: 5151104 [No Abstract] [Full Text] [Related]
35. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Hussain MA; Green N; Flynn DM; Hoffbrand AV Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469 [TBL] [Abstract][Full Text] [Related]
37. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)]. Lévy G; Bachelot C; Joannard A; Bost M Arch Fr Pediatr; 1980 May; 37(5):299-303. PubMed ID: 7469704 [TBL] [Abstract][Full Text] [Related]
38. New treatment for patients with iron overload. Griffith P; Burks J J Nurs Care; 1978 Sep; 11(9):12-4. PubMed ID: 308223 [No Abstract] [Full Text] [Related]
39. Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia. Vichinsky E Pediatrics; 2008 Jun; 121(6):1253-6. PubMed ID: 18519495 [No Abstract] [Full Text] [Related]